methoxsalen soft gelatin capsules / Generic mfg. - LARVOL DELTA

TYME Technologies, Inc. Announces SM-88 Poster at the American Association for Cancer Research (AACR) Annual Meeting 2022 (GlobeNewswire) - “Abstract Highlights: The initial studies were focused on assessing the effects of SM-88 (D/L-alpha-metyrosine; racemetyrosine) as a potential anti-cancer agent for ER+ tumor models that were either resistant or sensitive to antiestrogens agents and CDK4/6 inhibitors. The results that SM-88 alone showed antiproliferative effects in each of the sensitive and resistant cells lines, and that the combination of SM-88 and MPS had an additive effect in these models. Ongoing work is focused on further defining the biochemical pathways in drug sensitive and resistant cells that will further support the current clinical use of SM-88 in advanced ER+ /HER2- breast cancer (ClinicalTrials.gov Identifier: NCT04720664).”

P2 data • Breast Cancer • Estrogen Receptor Positive Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Oncology • Solid Tumor